Alun Bermingham

Alun Bermingham

Company: Revolution Medicines

Job title: Senior Director Discovery Sciences

Seminars:

Translating Frontier Oncology Targets to Outsmart Cancer™ 2:15 pm

Revolution Medicines (RevMed) has developed a series of Tri-Complex inhibitors targeting RAS(ON) RevMed RAS(ON) inhibitors work by sequestering Cyclophilin A to form an inhibitory complex with RAS mutant proteins, preventing pathway signalling Covalent RAS(ON) Tri-Complexes display sustained stability in biochemical and in vitro assays, and drive impressive regression in tumor xenograftsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.